Summit Therapeutics

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
9926.HK

Recent Articles

RELATED ARTICLES

  1. This biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer.
    HBM gets health boost from drug licensing deals
    2142.HK
  2. Drug maker Junshi seeks Swiss cure for cash woes
    1877.HK 688150.SHG
  3. Sales success comes with side effects for drug maker BeiGene
    BGNE.US 6160.HK
  4. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  5. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva